La Trobe

Altered phenotypic and functional characteristics of CD3(+)CD56(+) NKT-like cells in human gastric cancer

Download (4.78 MB)
journal contribution
posted on 2023-03-29, 05:57 authored by L-S Peng, F-Y Mao, Y-L Zhao, T-T Wang, N Chen, J-Y Zhang, P Cheng, W-H Li, Y-P Lv, Y-S Teng, G Guo, P Luo, Weisan ChenWeisan Chen, Q-M Zou, Y Zhuang
CD3+CD56+ natural killer T (NKT)-like cells are a group of CD3+ T cells sharing characteristics of NK and T cells and constitute a major component of host antitumor immune response in human cancer. However, the nature, function and clinical relevance of CD3+CD56+ NKT-like cells in human gastric cancer (GC) remain unclear. In this study, we showed that the frequencies of CD3+CD56+NKT-like cells in GC tumors were significantly decreased and low levels of tumor-infiltrating CD3+CD56+ NKT-like cells were positively correlated with poor survival and disease progression. Most CD3+CD56+NKT-like cells in GC tumors were CD45RA-CD27+/- central/effectormemory cells with decreased activity and lower expression levels of CD69, NKG2D and DNAM-1 than those in non-tumor tissues. We further observed that tumor-infiltrating CD3+CD56+ NKT-like cells had impaired effector function as shown by decreased IFN-γ, TNF-α, granzyme B and Ki-67 expression. Moreover, in vitro studies showed that soluble factors released from GC tumors could induce the functional impairment of CD3+CD56+ NKT-like cells. Collectively, our data indicate that decreased tumorinfiltrating CD3+CD56+ NKT-like cells with impaired effector function are associated with tumor progression and poor survival of GC patients, which may contribute to immune escape of GC.

Funding

This work was supported by grants of the National Natural Science Foundation of China (NSFC, No. 81502457 and No. 81402355).

History

Publication Date

2016-01-01

Journal

Oncotarget

Volume

7

Issue

34

Pagination

9p. (p. 55222-55230)

Publisher

Impact Journals

ISSN

1949-2553

Rights Statement

© The Authors 2016. Licensed under the Creative Commons Licence 3.0 https://creativecommons.org/licenses/by/3.0/. The authors allow anyone to download, reuse, reprint, modify, distribute, and/or copy articles in Oncotarget, so long as the original authors and source are cited. No permission is required from the authors or the publishers. For more information: https://www.oncotarget.com/editorial-policies/

Usage metrics

    Journal Articles

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC